Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Thymosin-beta-4-fragment

Ac-SDKP, Goralatide, Seraspenide

Quick Stats
Studies 83
Trials 3
Score 1
2004 pubmed

Factor XIIIa incorporates thymosin beta4 preferentially into the fibrin(ogen) alphaC-domains.

Makogonenko. Evgeny E; Goldstein. Allan L AL; Bishop. Paul D PD; Medved. Leonid L

Key Findings

  • Factor XIIIa covalently incorporates thymosin‑beta‑4 into fibrin and fibrinogen, with higher incorporation into fibrin.
  • The main attachment site is the COOH‑terminal region (residues 392‑610) of the alphaC‑domain of fibrinogen.
  • No significant non‑covalent interaction occurs between thymosin‑beta‑4 and fibrin(ogen) without activated factor XIIIa.

Practical Outcomes

  • For most biohackers, this research doesn’t change how you would use thymosin‑beta‑4, as it focuses on a biochemical detail of clot formation rather than a clear health benefit or dosing guideline. It suggests that taking the peptide could theoretically influence clot structure, so anyone considering it should be aware of potential effects on blood clotting and monitor any related health markers.

Summary

The study shows that an enzyme called factor XIIIa can attach the peptide thymosin‑beta‑4 to blood clot proteins (fibrin and fibrinogen), especially in a specific part of the clot protein called the alphaC‑domain. This attachment only happens when factor XIIIa is active, and it doesn’t happen through simple binding without the enzyme.

Abstract

It was shown recently that tissue transglutaminase and presumably plasma transglutaminase, factor XIIIa, can covalently incorporate into fibrin(ogen) a physiologically active peptide, thymosin beta(4) [(Huff et al. (2002) FASEB J. 16, 691-696]. To clarify the mechanism of this incorporation, we studied the interaction of thymosin beta(4) with fibrinogen, fibrin, and their recombinant fragments, the gamma-module (gamma-chain residues 148-411), and the alphaC-domain (Aalpha-chain residues 221-610) and its truncated variants by immunoblot and ELISA. No significant noncovalent interaction between them was detected in the absence of activated factor XIII, while in its presence thymosin beta(4) was effectively incorporated into fibrin and to a lesser extent into fibrinogen. The incorporation at physiological concentrations of fibrin(ogen) and factor XIII was significant with molar incorporation ratios of thymosin beta(4) to fibrinogen and fibrin of 0.2 and 0.4, respectively. Further experiments revealed that although activated factor XIII incorporates thymosin beta(4) into the isolated gamma-module and alphaC-domain, in fibrin the latter serves as the major incorporation site. This site was further localized to the COOH-terminal portion of the alphaC-domain including residues 392-610.

Study Information

Provider

pubmed

Year

2004

Date

2004-08-24T00:00:00.000Z

DOI

10.1021/bi049253l